Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$54 Mln
P/E Ratio
--
P/B Ratio
4.4
Industry P/E
--
Debt to Equity
0.01
ROE
-3.62 %
ROCE
313.37 %
Div. Yield
0 %
Book Value
2.03
EPS
-3.08
CFO
$-282.21 Mln
EBITDA
$-292.86 Mln
Net Profit
$-197.83 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
| 62.94 | 35.22 | 57.63 | -9.91 | -10.97 | -24.61 | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
vTv Therapeutics Inc. Class A (VTVT)
| 19.90 | -56.62 | -33.37 | -46.51 | 9.41 | -35.85 | -55.71 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.21 | 10,135.98 | 20.78 | 23.13 | |
| 302.88 | 8,668.61 | 21.55 | 58.42 | |
| 27.39 | 9,559.25 | -- | -28.77 | |
| 105.76 | 10,030.35 | 30.81 | 14.16 |
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally... administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC. Address: 3980 Premier Drive, High Point, NC, United States, 27265 Read more
CEO, President & Director
Mr. Paul J. Sekhri M.Sc.
CEO, President & Director
Mr. Paul J. Sekhri M.Sc.
Headquarters
High Point, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of vTv Therapeutics Inc Class A (VTVT) stood at $ 38 Mln as on 31-Dec-24
The share price of vTv Therapeutics Inc Class A (VTVT) is $22.50 (NASDAQ) as of 24-Apr-2025 16:00 EDT. vTv Therapeutics Inc Class A (VTVT) has given a return of -10.97% in the last 3 years.
vTv Therapeutics Inc Class A (VTVT) has a market capitalisation of $ 54 Mln as on 24-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of vTv Therapeutics Inc Class A (VTVT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the vTv Therapeutics Inc Class A (VTVT) and enter the required number of quantities and click on buy to purchase the shares of vTv Therapeutics Inc Class A (VTVT).
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC. Address: 3980 Premier Drive, High Point, NC, United States, 27265
The CEO & director of Mr. Paul J. Sekhri M.Sc.. is vTv Therapeutics Inc Class A (VTVT), and CFO & Sr. VP is Mr. Paul J. Sekhri M.Sc..
There is no promoter pledging in vTv Therapeutics Inc Class A (VTVT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| vTv Therapeutics Inc. Class A (VTVT) | Ratios |
|---|---|
|
Return on equity(%)
|
295.84
|
|
Operating margin(%)
|
-2222.71
|
|
Net Margin(%)
|
-1815.34
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of vTv Therapeutics Inc Class A (VTVT) was $0 Mln.
$1.95
(
